Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome-Reference-Cited by-同舟云学术

Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome

Published:2018-03-25 Issue:6 Volume:84 Page:1238-1249
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Bonanni Alice¹²,Calatroni Marta³,D'Alessandro Matteo¹,Signa Sara¹,Bertelli Enrica¹,Cioni Michela²,Di Marco Eddi⁴,Biassoni Roberto⁴,Caridi Gianluca²,Ingrasciotta Giulia¹⁵,Bertelli Roberta²,Di Donato Armando²,Bruschi Maurizio²,Canepa Alberto¹,Piaggio Giorgio¹,Ravani Pietro⁶,Ghiggeri Gian Marco¹²^ORCID

Affiliation:

1. Division of Nephrology, Dialysis, Transplantation; IRCCS Giannina Gaslini; Via Gerolamo Gaslini 5 Genoa 16148 Italy

2. Laboratory of Molecular Nephrology; IRCCS Giannina Gaslini; Genoa Italy

3. Dialysis and Transplantation Policlinico IRCCS Fondazione San Matteo and University of Pavia; Pavia Italy

4. Department of Translational Medicine; Istituto Giannina Gaslini; Largo G. Gaslini 5 Genoa 16147 Italy

5. Specialization School in Pediatrics; University of Brescia; Italy

6. Division of Nephrology; University of Calgary; 1403-29th Street NW Calgary AB T2N 2T9 Canada

Funder

Compagnia di San Paolo

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.13548/fullpdf

Reference48 articles.

1. Structure of the Fab fragment of therapeutic antibody ofatumumab provides insights into the recognition mechanism with CD20;Du;Mol Immunol,2009

2. Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma--a phase II trial;Furtado;Br J Haematol,2014

3. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial;Taylor;Ann Rheum Dis,2011

4. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study;Sorensen;Neurology,2014

5. Ofatumumab for rituximab-resistant nephrotic syndrome;Basu;N Engl J Med,2014

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Subcutaneous Rituximab in Idiopathic Nephrotic Syndrome;Kidney International Reports;2024-08

2. Therapeutic antibodies against cancer—A step toward the treatment;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024

3. Obinutuzumab in Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome in Children;Clinical Journal of the American Society of Nephrology;2023-09-06

4. Mechanisms and Clinical Research Progress of Rituximab in the Treatment of Adult Minimal Change Disease;Journal of Clinical Nephrology;2023-08-08

5. An unusual cause of diarrhea in a child with nephrotic syndrome: Answers;Pediatric Nephrology;2023-05-24